Nuformix plc (NFX) - Net Assets
Based on the latest financial reports, Nuformix plc (NFX) has net assets worth GBX754.93K GBX (≈ $91.85 USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.02 Million ≈ $123.97 USD) and total liabilities (GBX263.92K ≈ $32.11 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Nuformix plc balance sheet liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX754.93K |
| % of Total Assets | 74.1% |
| Annual Growth Rate | 10.52% |
| 5-Year Change | -84.07% |
| 10-Year Change | N/A |
| Growth Volatility | 56.66 |
Nuformix plc - Net Assets Trend (2014–2025)
This chart illustrates how Nuformix plc's net assets have evolved over time, based on quarterly financial data. Also explore Nuformix plc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Nuformix plc (2014–2025)
The table below shows the annual net assets of Nuformix plc from 2014 to 2025. For live valuation and market cap data, see NFX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | GBX754.93K ≈ $91.85 |
+5.50% |
| 2024-09-30 | GBX715.57K ≈ $87.06 |
-82.94% |
| 2023-09-30 | GBX4.20 Million ≈ $510.41 |
-0.78% |
| 2023-03-31 | GBX4.23 Million ≈ $514.45 |
-10.76% |
| 2022-03-31 | GBX4.74 Million ≈ $576.47 |
-16.68% |
| 2021-03-31 | GBX5.69 Million ≈ $691.85 |
+19.90% |
| 2020-03-31 | GBX4.74 Million ≈ $577.03 |
+24.30% |
| 2019-03-31 | GBX3.82 Million ≈ $464.22 |
-15.09% |
| 2018-03-31 | GBX4.49 Million ≈ $546.69 |
+2601.86% |
| 2017-03-31 | GBX-179.59K ≈ $-21.85 |
-135.75% |
| 2016-03-31 | GBX502.34K ≈ $61.12 |
-23.29% |
| 2015-12-31 | GBX654.83K ≈ $79.67 |
+690.71% |
| 2015-07-31 | GBX-110.86K ≈ $-13.49 |
-144.88% |
| 2014-07-31 | GBX247.00K ≈ $30.05 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nuformix plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 709942600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX1.41 Million | 186.44% |
| Other Comprehensive Income | GBX28.51K | 3.78% |
| Other Components | GBX6.84 Million | 905.39% |
| Total Equity | GBX754.93K | 100.00% |
Nuformix plc Competitors by Market Cap
The table below lists competitors of Nuformix plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AETHER CATALYST SOLUT.
F:2QZ
|
$44.09K |
|
MSP Recovery Inc
NASDAQ:MSPR
|
$44.42K |
|
Macau Property Opportunities Fund Ltd
LSE:MPO
|
$44.77K |
|
DongBang Medical
KQ:240550
|
$44.93K |
|
Oneiro Energy PLC
LSE:ONE
|
$43.33K |
|
Athelney Trust plc
LSE:ATY
|
$43.32K |
|
Aditxt Inc.
NASDAQ:ADTX
|
$43.31K |
|
S&W Seed Company
NASDAQ:SANW
|
$43.15K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nuformix plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 715,571 to 754,934, a change of 39,363 (5.5%).
- Net loss of 652,586 reduced equity.
- Other comprehensive income increased equity by 28,513.
- Other factors increased equity by 663,436.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-652.59K | -86.44% |
| Other Comprehensive Income | GBX28.51K | +3.78% |
| Other Changes | GBX663.44K | +87.88% |
| Total Change | GBX- | 5.50% |
Book Value vs Market Value Analysis
This analysis compares Nuformix plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 374.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 20.34x to 374.04x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-03-31 | GBX0.01 | GBX0.17 | x |
| 2017-03-31 | GBX0.00 | GBX0.17 | x |
| 2018-03-31 | GBX0.01 | GBX0.17 | x |
| 2019-03-31 | GBX0.01 | GBX0.17 | x |
| 2020-03-31 | GBX0.01 | GBX0.17 | x |
| 2021-03-31 | GBX0.01 | GBX0.17 | x |
| 2022-03-31 | GBX0.01 | GBX0.17 | x |
| 2023-03-31 | GBX0.01 | GBX0.17 | x |
| 2023-09-30 | GBX0.01 | GBX0.17 | x |
| 2024-09-30 | GBX0.00 | GBX0.17 | x |
| 2025-09-30 | GBX0.00 | GBX0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nuformix plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -86.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.35x
- Recent ROE (-86.44%) is below the historical average (-41.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 299.60% | 152.04% | 0.34x | 5.73x | GBX270.21K |
| 2015 | 0.00% | -117.33% | 0.62x | 0.00x | GBX-193.08K |
| 2016 | -69.76% | -57.68% | 1.12x | 1.08x | GBX-400.65K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-667.10K |
| 2018 | -40.91% | -12255.09% | 0.00x | 1.12x | GBX-2.29 Million |
| 2019 | -43.54% | -272.33% | 0.13x | 1.21x | GBX-2.04 Million |
| 2020 | -15.95% | -141.38% | 0.10x | 1.08x | GBX-1.23 Million |
| 2021 | -22.04% | -641.01% | 0.03x | 1.06x | GBX-1.82 Million |
| 2022 | -23.41% | -2217.99% | 0.01x | 1.05x | GBX-1.58 Million |
| 2023 | -17.98% | 0.00% | 0.00x | 1.06x | GBX-1.18 Million |
| 2023 | -13.66% | 0.00% | 0.00x | 1.05x | GBX-992.48K |
| 2024 | -508.89% | 0.00% | 0.00x | 1.36x | GBX-3.71 Million |
| 2025 | -86.44% | 0.00% | 0.00x | 1.35x | GBX-728.08K |
Industry Comparison
This section compares Nuformix plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,864,748
- Average return on equity (ROE) among peers: -251.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nuformix plc (NFX) | GBX754.93K | 299.60% | 0.35x | $43.64K |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Fusion Antibodies PLC (FAB) | $50.13K | -935.06% | 5.06x | $193.60K |
| Faron Pharmaceuticals Oy (FARN) | $10.88 Million | -85.40% | 0.59x | $575.13K |
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more